cardinal health specialty alliance

News

Cardinal Health, Solaris and urology

Cardinal Health expands urology focus with $1.9bn Solaris Health deal

The acquisition reflects Cardinal’s expanded focus on urology in pursuit of higher growth margin versus drug distribution.

Fierce Healthcare · 58m

Cardinal Health builds out urology focus with $1.9B deal for Solaris Health

Cardinal Health acquired Solaris Health as it continues to build out its multispecialty management services organization platform. | Cardinal Health MSO platforms will reach about 3,000 providers in 32 states once the Solaris Health deal closes,

The Wall Street Journal on MSN · 1d

Cardinal Health Shares Sink on Mixed Results, $1.9 Billion Solaris Health Deal

Recent acquisitions helped to slightly lift the healthcare-products distributor’s profit and revenue, as the company faces lingering malaise stemming from its OptumRx contract expiration.

Cardinal Health announces the addition of Solaris Health, the country's leading urology MSO, to The Specialty Alliance

Cardinal Health (NYSE: CAH) today announced that The Specialty Alliance, its multi-specialty management services organization ...

Stocktwits on MSN1d

Cardinal Health To Provide $1.9B To Specialty Alliance Division To Enable Solaris Health Acquisition: More Details Inside

Pharmaceutical distributor Cardinal Health (CAH) on Tuesday said its multi-specialty management services organization (MSO) platform is set to acquire healthcare platform Solaris Health. Cardinal ...

PE Hub1d

Cardinal Health’s The Specialty Alliance to acquire urology MSO Solaris Health from Lee Equity

Cardinal Health will provide approximately $1.9 billion in cash to The Specialty Alliance to enable the acquisition.

22hon MSN

Why Cardinal Health Stock Was Tumbling on Tuesday

The healthcare conglomerate handily beat on the bottom line in its latest reported quarter, but that's not what the market was paying attention to.

Cardinal Health Q4 Preview: Accelerating Autoimmune, Urology, And Oncology, Buy

Cardinal Health, Inc. is rated a Buy with a $239 fair value, driven by specialty growth in autoimmune, urology & oncology.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results